Journal
TOXINS
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/toxins10120542
Keywords
Pore-forming toxin; bacterial infection; virulence factor; pharmacology; adjunctive therapy
Categories
Funding
- National Institutes of Health [R01AI077780, R01HL125352]
- UCSD NIH/NIGMS Training Program in Molecular and Cellular Pharmacology [T32GM007752]
- PhRMA Foundation Fellowship
Ask authors/readers for more resources
For many of the most important human bacterial infections, invasive disease severity is fueled by the cell damaging and pro-inflammatory effects of secreted pore-forming toxins (PFTs). Isogenic PFT-knockout mutants, e.g., Staphylococcus aureus lacking -toxin or Streptococcus pneumoniae deficient in pneumolysin, show attenuation in animal infection models. This knowledge has inspired multi-model investigations of strategies to neutralize PFTs or counteract their toxicity as a novel pharmacological approach to ameliorate disease pathogenesis in clinical disease. Promising examples of small molecule, antibody or nanotherapeutic drug candidates that directly bind and neutralize PFTs, block their oligomerization or membrane receptor interactions, plug establishment membrane pores, or boost host cell resiliency to withstand PFT action have emerged. The present review highlights these new concepts, with a special focus on -PFTs produced by leading invasive human Gram-positive bacterial pathogens. Such anti-virulence therapies could be applied as an adjunctive therapy to antibiotic-sensitive and -resistant strains alike, and further could be free of deleterious effects that deplete the normal microflora.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available